Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Prostate Cancer Screening Has Yet To Prove Its Worth
The recent release of two large randomized trials suggests that if there is a benefit of screening, it is, at best, small, says a new report in CA: A Cancer Journal for Clinicians. Authored by Otis W. Brawley, M.D. of the American Cancer Society and Donna Ankerst, Ph.D. and Ian M. Thompson, M.D. of the University of Texas Health Science Center at San Antonio, the review says because prostate cancer is virtually ubiquitous in men as they age, it is clear that a goal of "finding more cancers" is not acceptable. Instead, public health principles demand that screening must reduce the risk of death from prostate cancer, reduce the suffering from prostate cancer, or reduce health care costs when compared with a non-screening scenario. The authors suggest prostate cancer screening has yet to reach one of these standards to date.

Investigational Drug Shows Promise As Treatment For Overexposure To Common Cancer Chemotherapy
The emergency use of an investigational drug has yielded promising results in reducing the potentially fatal side effects of the widely used cancer chemotherapy 5-fluorouracil (5-FU), according to clinical data that will be reported June 1 at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando.1
News of the day
GlaxoSmithKline And Genmab Announce Top-line Results For Ofatumumab In Rheumatoid Arthritis
GlaxoSmithKline (GSK) and Genmab A/S (OMX: GEN) announced preliminary top-line results from a Phase III study of ofatumumab administered intravenously for the treatment of rheumatoid arthritis (RA) in patients who had an inadequate response to methotrexate. The study met the primary endpoint, ACR20 at 24 weeks, which indicates a 20 percent or greater improvement in the number of swollen and tender joints, as well as improvements in other disease-activity measures.
Diagnostics

Long Beach PET Imaging Center To Relocate To New Facility; Enhances Imaging Offering With Addition Of State-of-the-Art PET/CT Scanner

Long Beach PET Imaging Center, a leading diagnostic imaging center in the Long Beach, Calif.-area, announced it has relocated to a new, expanded facility at 2708 East Willow, Signal Hill, CA 90755, 562-427-0714, adjacent to Liberty Pacific Medical Imaging. The relocation is expected to be completed in August 2009. During the relocation process, all services including PET/CT and CT will remain in full operation without any interruption. Long Beach PET Imaging Center has been providing imaging services including PET/CT to patients, payors and physicians throughout Long Beach and surrounding Southern California communities for more than eight years. During this time, Long Beach PET Imaging Center has established a solid reputation for quality patient care and highly personalized radiology services. Long Beach PET Imaging Center will bring that same commitment to patients, payors and physicians from its new facility along with enhanced capabilities as it installs the first, state-of-the-art PET/CT high definition (HD) scanner available within a 30-mile radius of the facility. The Siemens Biograph 40 TruePoint PET/CT with HD and True-V technologies performs PET/CT scans in about 10 minutes, less than half of the time of traditional PET/CT studies, which can take anywhere from 25-40 minutes. Furthermore, the HD feature of the Biograph 40 TruePoint PET/CT scanner allows physicians to detect the smallest lesions detectable on any scanner (those not normally found in today"s technologies) by providing better clarity, better resolution and better uniformity. The Siemens Biograph 40 TruePoint PET/CT is the only high definition scanner available in the marketplace today. Additionally, the Siemens Biograph 40 TruePoint PET/CT combines positron emission technology and computed tomography. The PET provides functional information at the molecular level while the CT offers anatomical data. Other features of the Siemens Biograph TruePoint PET/CT include a comfortable award-winning table design; non-claustrophobic open gantry system; proven crystal technology; the best PET and CT resolution available; the highest resolution at any pitch; the highest standard rotational speed; and a seamless upgrade path. "We are very excited to bring the medical communities of Long Beach and Orange County the first HD PET/CT scanner and the only one within a 30-mile radius of our new facility. This technology will truly make a difference in the diagnostic imaging capability afforded patients and brings the community the benefit of early cancer detection. The high definition is what allows us to see the smallest of lesions detectable in imaging today. "The new Long Beach PET Imaging Center will allow patients, payors and physicians the ability to access industry-leading PET and CT scans as well as advanced diagnostic capabilities in the areas of cardiology, oncology, and neurology with the addition of the Siemens Biograph 40 TruePoint PET/CT. We look forward to continuing to serve the community with revolutionary technologies from our new, expanded, state-of-the art facility for years to come," Dr. Dobkin concluded. Dr. Dobkin has been an imaging specialist for nearly 20 years. Prior to his work at Long Beach PET, he served in this capacity at MEMRAD Medical Group, Inc., also in Long Beach. Dobkin was Assistant Professor of Radiology at Mallinckrodt Institute of Radiology at Washington University School of Medicine in St. Louis. He also was a staff physician at The Cancer Foundation of Santa Barbara in Santa Barbara, Calif., and an Assistant Professor of Radiology at the University of Pittsburgh, School of Medicine in Pittsburgh. He serves as an interpreting physician (reading radiologist) at over 20 medical groups throughout Washington and California. He is a published author and seasoned speaker on radiology and imaging. Long Beach PET Imaging Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009